EA
KPTI icon

Emerald Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Emerald Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,098
Closed -$489K – 296
2021
Q1 		$489K Sell
3,098
-118,421
-97% -$25M 0.02% 198
2020
Q4 		$28.2M Buy
121,519
+14,635
+14% +$3.39M 0.94% 37
2020
Q3 		$23.4M Buy
106,884
+23,937
+29% +$5.86M 0.96% 38
2020
Q2 		$23.6M Buy
82,947
+13,244
+19% +$3.92M 1.03% 35
2020
Q1 		$20.1M Buy
69,703
+36,286
+109% +$10M 1.16% 25
2019
Q4 		$9.61M Sell
33,417
-66,355
-67% -$14.4M 0.41% 94
2019
Q3 		$14.4M Buy
99,772
+1,356
+1% +$184K 0.67% 56
2019
Q2 		$8.84M Sell
98,416
-2,124
-2% -$171K 0.36% 100
2019
Q1 		$8.81M Buy
100,540
+3,442
+4% +$382K 0.36% 103
2018
Q4 		$13.6M Buy
97,098
+50,827
+110% +$8.57M 0.67% 58
2018
Q3 		$11.8M Buy
46,271
+8,850
+24% +$2.45M 0.43% 97
2018
Q2 		$9.54M Buy
+37,421
New +$9.26M 0.36% 107

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Emerald Advisers's KPTI Position: Q2 2021 in Review

Emerald Advisers sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 3,098 shares — an estimated $489K sold.

Emerald Advisers first reported a position in KPTI in Q2 2018 and held it in 12 quarters. The position peaked at $28.2M in Q4 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Emerald Advisers reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Emerald Advisers sold 3,098 Karyopharm Therapeutics shares in Q2 2021, an estimated $489K.
  • Emerald Advisers first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 12 quarters.
  • Emerald Advisers's Karyopharm Therapeutics position peaked at $28.2M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Emerald Advisers's 13F filing for Q2 2021, filed 29 Jul 2021.